Gram-positive bacteria cause the majority of skin and soft tissue infections (SSTIs), resulting in the most common reason for clinic visits in the United States. Recently, it was discovered that Grampositive pathogens use a unique heme biosynthesis pathway, which implicates this pathway as a target for development of antibacterial therapies. We report here the identification of a small-molecule activator of coproporphyrinogen oxidase (CgoX) from Gram-positive bacteria, an enzyme essential for heme biosynthesis. Activation of CgoX induces accumulation of coproporphyrin III and leads to photosensitization of Gram-positive pathogens. In combination with light, CgoX activation reduces bacterial burden in murine models of SSTI. Thus, small-molecule activation of CgoX represents an effective strategy for the development of light-based antimicrobial therapies.
bacteria | photosensitization | CgoX | heme | antibiotic S kin and soft tissue infections (SSTIs) are responsible for a majority of visits to hospitals and clinics in the United States, accounting for ∼14 million ambulatory care visits each year (1) . Furthermore, ∼10% of hospitalized patients suffer from an SSTI (1) . These infections are typically caused by Gram-positive bacteria including Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes, and Bacillus anthracis, the causative agents of "staph infections," hospital-acquired infections, acne, and cutaneous anthrax, respectively (1) (2) (3) (4) . S. aureus and P. acnes are the most prevalent causative agents of SSTIs (1) (2) (3) (4) . In fact over 90% of the world's population will suffer from acne over the course of their lifetime, leading to annual direct costs of over $3 billion (1, 2, 5, 6) . The threat of these pathogens is compounded by the tremendous rise in antibiotic resistance, reducing the efficacy of the existing antibacterial armamentarium (1, 3, 4) . Identifying new drug targets to treat SSTIs is paramount to enable the development of novel therapeutics.
Heme biosynthesis is conserved across all domains of life, and heme is used for a diverse range of processes within cells. Until recently, it was thought that the heme biosynthesis pathway was conserved across all species, limiting its utility as a potential therapeutic target to treat infectious diseases. However, Dailey et al. (7, 8) discovered that Gram-positive bacteria use a distinct pathway to synthesize the critical cellular cofactor heme (Fig. 1A) . Specifically, Gram-positive heme biosynthesis diverges at the conversion of coproporphyrinogen III (CPGIII) to coproporphyrin III (CPIII) through a six-electron oxidation by coproporphyrinogen oxidase (CgoX, formally known as HemY), as opposed to being converted to protoporphyrin IX (PPIX) in the classical pathway by a distinct series of enzymes (7, 9, 10) . The divergence of the heme biosynthesis machinery between humans and Gram-positive bacteria provides a unique opportunity for the development of antibiotics targeting this pathway as a strategy to treat infections.
Small-molecule VU0038882 ('882) was previously identified in a screen for activators of the S. aureus heme-sensing system twocomponent system (HssRS) (11) (12) (13) (Fig. 1B) . Upon activation, HssRS induces the expression of the heme-regulated transporter (HrtAB) to alleviate heme toxicity (11) (12) (13) . HssRS activation is triggered by massive accumulation of heme in '882-exposed bacteria (11) . In addition to activating HssRS, treatment with '882 induces toxicity to bacteria undergoing fermentation by impacting iron-sulfur cluster biogenesis (11, 14) . Through a medicinal chemistry approach, the HssRS-activating properties of '882 were decoupled from its toxicity, suggesting two distinct cellular targets for this small molecule (11, 14, 15) . Before this investigation, the mechanism by which '882 activates heme biosynthesis to trigger HssRS had not been uncovered.
We report here the identification of the cellular target of '882 responsible for inducing heme biosynthesis through the use of a P hrt -driven suicide strain. '882 activates CgoX from Grampositive bacteria, an enzyme essential for heme biosynthesis. Activation of CgoX induces accumulation of the product of the Significance Skin and soft tissue infections (SSTIs) account for a majority of visits to hospitals and clinics in the United States and are typically caused by Gram-positive pathogens. Recently, it was discovered that Gram-positive bacteria use a unique pathway to synthesize the critical cellular cofactor heme. The divergence of the heme biosynthesis pathways between humans and Gram-positive bacteria provides a unique opportunity for the development of new antibiotics targeting this pathway. We report here the identification of a small-molecule activator of coproporphyrinogen oxidase (CgoX) from Gram-positive bacteria that induces accumulation of coproporphyrin III and leads to photosensitization of Gram-positive pathogens. In combination with light, CgoX activation reduces bacterial burden in murine models of SSTI.
reaction, CPIII, a photoreactive molecule of demonstrated utility in treating bacterial infections (6, 16, 17) . Photodynamic therapy (PDT) uses a photosensitizing molecule activated by a specific wavelength of light to produce reactive oxygen species that lead to cell death (6) . Most US Food and Drug Administration-approved photosensitizers are aminolevulinic acid (ALA) derivatives, which serve as prodrugs through their conversion to porphyrins in the heme biosynthetic pathway (6) . Through '882-dependent activation of CgoX, CPIII accumulates in a similar manner, inducing photosensitization specifically in Gram-positive bacteria, and '882-PDT reduces bacterial burden in murine models of SSTI (Fig. S1 ). Thus, small-molecule activation of CgoX represents a promising strategy for the development of light-based antimicrobial therapies.
Results
Construction of an '882-Responsive Suicide Strain. To identify the target of '882, a suicide strain was created enabling selection of S. aureus strains that are unresponsive to '882. Because '882 is not toxic to wild-type (WT) bacteria, a genetic approach was used to engineer toxicity to S. aureus upon treatment with '882. S. aureus hrtAB was replaced with two copies of the gene encoding the Escherichia coli RNA interferase toxin RelE under the control of the native hrtAB promoter to inhibit growth upon activation of HssRS (Fig. 1C) . Dual copies of relE were used to avoid selection of toxin-inactivating mutations. S. aureus hrtAB::relE grows equivalently to WT in the absence of heme or '882. Upon HssRS induction by heme or '882, hrtAB::relE is unable to grow (Fig. 1D) . A strain lacking the hrtB permease (ΔhrtB) was used to ensure that '882 does not induce heme toxicity at tested concentrations. These results establish this suicide strain as a powerful tool to identify suppressor mutants unresponsive to '882.
Selection of '882-Resistant Suicide Strains. Isolates of hrtAB::relE exhibiting spontaneous resistance to '882 were identified at a frequency of 0.0079%, and the stability of resistance was ensured through serial passage. Genomic DNA was isolated and the hssRS/hrtAB locus was sequenced. Whole-genome sequencing was performed on isolates lacking mutations in hssRS/Phrt to identify mutations conferring resistance to '882 in the hrtAB::relE strain background. This analysis revealed a T183K mutation in CgoX, an enzyme required for heme biosynthesis. The CgoX T183K mutation was reconstructed in WT S. aureus (CgoX.T183K), and this strain exhibits normal growth, suggesting the CgoX T183K mutation prevents the response of S. aureus to '882 without restricting heme biosynthesis, as seen in a strain lacking CgoX (ΔCgoX) (18) (Fig. 1E ). In addition, the T183K mutation abolished '882 sensing to the same level as ΔhssRS, whereas heme sensing remained intact (Fig. 1F ). Taken together, these results demonstrate that the CgoX T183K mutation prevents '882-induced activation of hrtAB in S. aureus.
'882 Induces CPIII Accumulation. To determine the impact of '882 on the heme biosynthesis pathway, intermediates of heme biosynthesis were quantified following '882 exposure. Porphobilinogen (PBG), an early heme biosynthetic precursor, is unaffected by '882 ( Fig. 1A and Fig. S2 ). In contrast, CPIII, the product of CgoX, is greatly increased following '882 treatment (Fig. 1 A and G) . Notably, CPIII accumulation is not observed in CgoX.T183K or ΔCgoX upon '882 treatment (Fig. 1G) . CPIII is the only fluorescent molecule in the heme biosynthesis pathway, and '882 exposure triggers dramatic fluorescence in S. aureus (Fig. 1G, Inset) . The HPLC fraction corresponding to the elution time of the CPIII standard was analyzed by LC-MS/MS and confirmed to be CPIII (Fig. S3 ). These results demonstrate that '882 exposure leads to accumulation of CPIII in S. aureus and implicate CgoX as a candidate target of the molecule.
'882 Activates CgoX from Gram-Positive Bacteria in Vitro. To determine whether '882 directly activates S. aureus CgoX, recombinant S. aureus WT CgoX and CgoX T183K were purified. Importantly, these two enzymes display similar K m and V max values, demonstrating the T183K mutation does not affect baseline CgoX activity (Fig. 2G  and Fig. S4A ). Upon treatment with '882, WT CgoX displayed 205% activity with an AC 150 of 92 nM, whereas the T183K mutant did not respond to '882 at concentrations up to 10 μM (Fig. 3 A and G) . These data establish '882 as a small-molecule activator of CgoX.
To determine whether '882 retains activity against CgoX from other Gram-positive organisms, recombinant Bacillus subtilis and P. acnes CgoX were purified (7) . K m and V max values were determined to characterize baseline activity of the enzymes, and each was tested for '882-induced activation (Fig. 2 B and G and Fig.   S4B ). '882 activates CgoX from B. subtilis and P. acnes with AC 150 values of 42 and 16 nM, respectively (Fig. 2 B and G) . Importantly, human HemY, a protoporphyrinogen oxidase as opposed to a coproporphyrinogen oxidase, did not respond to '882 treatment ( Fig. 2C and Fig. S4C ). These results establish '882 as a smallmolecule activator of CgoX from Gram-positive bacteria.
Structure-Activity Relationship Studies of '882. Recently, a series of structural analogs of '882 were prepared and screened in a phenotypic HssRS activation assay using a XylE reporter gene to monitor transcription of hrtAB as a response to heme accumulation Table 1) . These analogs were assayed in the CgoX activation assay using WT and T183K mutant enzymes (Table 1) . Three analogs, b, d, and l, proved superior or comparable to '882 as CgoX activators in vitro. Notably, none of these more potent activators exhibit increased ability to trigger hrtAB expression in S. aureus over that of '882, suggesting that these compounds do not have improved bioavailability over '882 in staphylococcal cells. In addition, these '882 derivatives are also inactive against the T183K mutant, suggesting all four diarylpyrazoles share a common binding site. The remaining eight diarylpryazoles were equally inactive when assayed against CgoX or the T183K mutant. Collectively, these structure-activity relationship studies support activation of CgoX by a common allosteric binding site.
Structural Analysis of the '882-CgoX Interaction. To gain insight into the potential binding site of '882 within CgoX, the previously solved crystal structure of B. subtilis CgoX was interrogated (19) (Fig. 2D) . Based on the location of S. aureus T183 within CgoX, a nearby amino acid, N186, was implicated as potentially important due to its proximity on a short helix facing a cleft leading into the active site (Fig. 2 D and E) . The N186 residue was mutated to tyrosine, phenylalanine, or alanine and the activity of the mutant enzyme was examined in the presence or absence of '882 (Fig. 2 F and G and Fig. S4D ). CgoX N186Y and CgoX N186F exhibit increased baseline activity relative to WT CgoX, suggesting this region is important for positive enzyme regulation (Fig. 2G and Fig. S4D ). Consistent with this, all three mutations abolish the ability of CgoX to respond to '882 treatment (Fig. 2 F  and G) . Importantly, the helix containing these residues is in a distinct region from the active site of the molecule (Fig. 2D) . Taken together, these data support a model whereby '882 binds to the region of CgoX containing residues 183-186 and acts as an allosteric modulator of enzyme activity. Mutations in this portion of the enzyme may mimic '882-induced changes in tertiary structure leading to enzyme activation.
In Silico Docking Identifies a Functional Domain Important for '882
Activation. Despite significant efforts, we were unsuccessful in our attempts to solve the complete crystal structure of '882 in complex with CgoX from various Gram-positive organisms. A flexible loop encompasses residues 183-186 that were identified in our initial mutational analysis. Importantly, previously published structures of CgoX are also incomplete in this region (19, 20) . Therefore, to further our understanding of the functional domain required for '882 activity in the absence of a crystal structure, the '882-CgoX interaction was modeled by in silico docking to identify additional residues that may be required for '882-induced activity of CgoX. Based upon this analysis, six more residues within CgoX were selected for mutational analysis to interrogate their importance for '882-dependent activation (Fig.  3A) . Mutations were made in S. aureus CgoX, creating the enzyme variants V146M, M167F, Y171A, F184A, F187W, and D450Y. Upon induction, V146M, Y171A, F184A, and D450Y led to unstable enzymes that could not be purified (Fig. S5) . CgoX M167F and F187W expressed equivalently to WT (Fig.  S5) , were purified, and interrogated for '882-induced activation. Both mutations inhibited the activation of CgoX by '882 (Fig.  3B) . Taken together, these data begin to define a pocket within The two residues used to guide the docking are shown in cyan, whereas the two additional residues that were identified by the modeling approach and confirmed to have the desired disruption of '882 activity are shown in red. Structural analysis was performed on the B. subtilis crystal structure; homologous residue numbers to the S. aureus sequence are displayed (19) . (B) CgoX activity was assayed with '882 and 5 μM CPGIII. (C) Structural model highlighting the same four residues as in the boxplot in the B. subtilis structure (19) .
CgoX that appears to be required for '882-dependent activation of the enzyme (Fig. 3C) .
CgoX Activation Induces Photosensitization of Gram-Positive Bacteria.
PDT is frequently used to treat bacterial skin infections and involves the use of a photosensitizer and a light source to destroy cells through the production of reactive oxygen species (6) . Porphyrin intermediates of the heme biosynthesis pathway are the most common photosensitizers used in clinics. The production of porphyrin intermediates is often up-regulated through the addition of ALA, the first committed precursor in the heme biosynthetic pathway (Fig. 1A) . A major limitation of ALA-PDT for the treatment of infectious diseases is the lack of specificity of this therapy, which induces photosensitivity in both bacterial and human cells. Due to the specificity of '882 for CgoX from Grampositive bacteria, this molecule should selectively sensitize bacteria to light while avoiding host toxicity. To test this hypothesis, various strains of S. aureus were grown in the presence of ALA, '882, or both and exposed to 395-nm light, the absorbance maximum for CPIII as determined experimentally (data not shown). Both ALA and '882 treatment led to significant growth inhibition of S. aureus following exposure to 68 J/cm 2 light (Fig. 4A ). An additive effect was seen when '882 and ALA were in combination, likely due to ALA increasing precursor availability for CgoX.
Notably, ALA and '882 combined decreased S. aureus viability by six logs compared with untreated cells (Fig. 4A) . The toxicity of '882-PDT is conserved across some of the most important causes of human skin infections, including S. epidermidis, Staphylococcus haemolyticus, Staphylococcus lugdunensis, B. anthracis, and P. acnes (Fig. 4 B-D) . These results establish the utility of '882-PDT as a potential therapeutic for the treatment of skin infections caused by Gram-positive bacteria.
'882-PDT Decreases Bacterial Burdens in Vivo. To determine the in vivo efficacy of '882-PDT, a murine model of superficial S. aureus skin infection was used, which leads to considerable skin ulceration (21) . Mice infected with S. aureus USA300 LAC and treated with '882-PDT or '882/ALA-PDT exhibited significantly lower bacterial burden per wound following infection compared with untreated animals (Fig. 4G) . Histologically, all groups showed varying degrees of inflammation, with neutrophils being the most abundant cells present; however, bacterial burden was noticeably reduced in '882-PDT-and '882/ALA-PDT-treated samples (Fig. 4 E and F) . Topical administration of 2% mupirocin ointment, as a positive control antibiotic, also significantly reduced bacterial burden compared with untreated mice. (Fig. 4G) .
To evaluate the broad utility of '882-PDT as a therapy for common skin infections, the efficacy of '882-PDT in a murine model of P. acnes infection was determined. Both '882-PDT and '882/ALA-PDT led to a significant decrease in bacterial burden compared with untreated mice, highlighting the utility of '882 as a possible compound for the treatment of acne (Fig. 4H) . Taken together, these findings establish PDT coupled with small-molecule activation of CgoX as an effective therapeutic strategy to specifically target Gram-positive pathogens.
Discussion
These results define the small-molecule '882 as an activator of Gram-positive CgoX. Treatment with '882 leads to massive heme accumulation resulting in HssRS activation in S. aureus. Residues required for '882-induced CgoX activation have been identified, thereby revealing a functional domain involved in the activation of CgoX. In addition, treatment with '882 leads to photosensitization of Gram-positive bacteria, reducing bacterial burdens in vivo. Taken together, these results establish '882 as an activator of Gram-positive CgoX and provide proof-of-principle for small-molecule activation of CgoX as a potential therapeutic strategy for the treatment of bacterial infections.
Synthetic small-molecule activators are rare, with only a handful identified to date (22) . Identifying the targets of small molecules is a major obstacle in biomedical research (23) (24) (25) . Phenotypic high-throughput screens using small-molecule libraries often result in the identification of numerous molecules with unknown targets. Several approaches have been successful in identifying intracellular targets of small molecules (26) (27) (28) (29) (30) (31) (32) . Here, we report a genetic selection strategy based on the creation of a suicide strain that enables the identification of spontaneous resistant mutants to an activating compound that is typically nontoxic. This strategy can be adapted to a variety of systems where a small molecule activates a specific gene expression program, and may enable the identification of targets for numerous small-molecule activators.
The mechanisms by which heme biosynthesis is regulated in Gram-positive bacteria are largely unknown (9) . The identification of '882 as an activator of CgoX establishes this molecule as a valuable tool for interrogating the heme biosynthetic pathway in Gram-positive bacteria to further understand the synthesis of this essential cofactor. Interestingly, it has previously been demonstrated that CgoX activity is modulated in vitro to a similar extent by addition of ChdC (previously known as HemQ), the terminal enzyme in the Gram-positive heme biosynthesis pathway (33) . This suggests that the interaction of CgoX with '882 may not be a random occurrence but may represent an inappropriate hijacking of a normal in vivo regulatory mechanism. The '882-dependent activation of heme biosynthesis represents a valuable tool for studying the regulation of heme biosynthesis in Gram-positive bacteria.
Notably, enzyme activators have numerous properties that make them ideal therapeutics (22) . Whereas inhibitors often require the ability to inhibit the enzyme by 90%, activators can induce phenotypes with small increases in enzyme activity, indicating that derivatives of '882 with slight increases in activity could lead to dramatic increases in CPIII accumulation and therefore antibacterial properties (22) . Specifically, this has been seen with small-molecule activators of glucokinase, where a 1.5-fold increase in enzymatic activity has shown significant effects in vivo. These molecules are now used as therapeutics for diabetes (22, (34) (35) (36) .
In addition, inhibitors often bind active sites of enzymes, which are typically well conserved across homologous enzymes. In contrast, activators often bind allosteric sites, which are less well conserved across enzymes, thus increasing specificity and limiting off-target effects (22, 34, 37) . Structural analysis of the '882-CgoX interaction has identified a functional domain of CgoX that suggests an allosteric mechanism of action for '882-induced activation (Figs. 2 and 3 ). In addition, we have identified specific residues that when mutated increase activity, further supporting that this portion of the enzyme is important in positive regulation (Fig. 2) . Therefore, '882 and its derivatives have value as both probes of heme biosynthesis as well as small-molecule photosensitizers for the treatment of bacterial infections.
The use of PDT has begun to expand beyond SSTIs. Gastrointestinal endoscopes have been developed that emit wavelengths that activate porphyrins in patients to detect cancer, and similar strategies have been interrogated for their ability to treat gastrointestinal infections (38, 39) . Osteomyelitis and contamination of orthopedic devices are some of the most common invasive bacterial infections, and PDT strategies to combat these infections are being developed (40) (41) (42) (43) (44) (45) (46) . Finally, PDT-based strategies are in development for a variety of other diseases, including parasitic, dental, and sinus infections (47, 48) . One of the key limitations for PDT approaches involving photosensitizers that need to be activated with light at shorter wavelengths (below 500 nm) is the lack of deep-tissue penetration of light at those wavelengths. Therefore, the development of strategies to increase the penetration of light may considerably improve the therapeutic potential of porphyrin-based PDT. As the utility of PDT-based therapies expands, so too will the potential clinical utility of small-molecule activators of CgoX.
The ability of '882 to specifically photosensitize Gram-positive bacteria circumvents the nonspecific nature of ALA-PDT, which has limited the value of ALA-PDT for the treatment of infectious diseases (6, 49, 50) . Furthermore, this provides proof-of-concept that activation of bacterial porphyrin production through specific activation of CgoX is a viable therapeutic strategy that could be adapted to Gram-negative bacteria and other infectious diseases (6, 16, 47) . Therefore, the development of '882-PDT has the potential to significantly expand the value of light-based therapies for the treatment of the most common causes of skin infections.
Materials and Methods
Descriptions of growth conditions, strain construction, suicide strain selection experiments, genomic analysis, heme precursor quantification, promoter activity assays, CgoX activity assays, in silico docking studies, photosensitivity assays, superficial skin infection studies, and chemical synthesis can be found in SI Materials and Methods. Bacterial strains, expression constructs, plasmids, and primers used in this study can be found in Tables S1-S4. All research involving animals described in this paper was reviewed and approved by the Vanderbilt University Institutional Animal Care and Use Committee.
